Experts from industry and academia will discuss the bionic pancreas, bariatric surgery, the gut microbiome, obesity, and emerging therapies to target Type 1 and Type 2 diabetes in sessions and panels geared towards novel therapeutic strategies, drug discovery, and partnering with pharmaceuticals, biotech firms, and academic institutions.